CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,402 enrolled
Drug / intervention
Prizbind®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02946931
NCT02946931N/ACompleted

The Drug Use-results Survey (All-Case Surveillance) on Prizbind® for Intravenous Solution 2.5 g in Japan

Boehringer Ingelheim·observational·Posted Oct 27, 2016·Updated Sep 9, 2022

In Brief

An observational study evaluating Prizbind® for Hemorrhage. Completed, enrolled 1,402 participants across 1 site.

Detailed Summary

To evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical condition.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhage
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 27, 2016
Enrollment StartNov 18, 2016
Primary CompletionNov 3, 2020
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.7 years ago

Interventions

Prizbind®drug

Prizbind®